Intranasal formulation
    79.
    发明公开
    Intranasal formulation 失效
    Formulierungfürintranasale Verwendungen。

    公开(公告)号:EP0047122A2

    公开(公告)日:1982-03-10

    申请号:EP81303870.0

    申请日:1981-08-25

    CPC分类号: A61K31/415 A61K9/0043

    摘要: Intranasal formulations for antiviral benzimidazole compounds are disclosed. The formulations contain the active ingredient; a non-ionic, surface-active agent with a HLB number from 12 to 16; and a propellant.

    摘要翻译: 公开了用于抗病毒苯并咪唑化合物的鼻内制剂。 制剂含有活性成分; HLB为12至16的非离子表面活性剂; 和推进剂。

    Separation of syn and anti 1-alkylsulfonyl-2-amino-5(6)hydroximinomethylbenzimidazole derivatives
    80.
    发明公开
    Separation of syn and anti 1-alkylsulfonyl-2-amino-5(6)hydroximinomethylbenzimidazole derivatives 失效
    Trennung von syn-和抗-1-烷基磺酰基-2-氨基-5(6)肟基甲基苯并咪唑衍生物。

    公开(公告)号:EP0015339A1

    公开(公告)日:1980-09-17

    申请号:EP79302272.4

    申请日:1979-10-19

    IPC分类号: C07D235/30

    CPC分类号: C07D235/30

    摘要: To separate the syn and anti oximes of the formula
    wherein R 1 is C 1 -C 5 alkyl; and R 2 is phenyl, or phenyl substituted by C 1 -C 4 alkyl, C 1 -C 4 alkoxy, chloro, bromo, iodo, nitro or trifluoromethyl, e.g. 1-isopropylsulfonyl-2-amino-6-(a-hydroximinobenzyl)-benzimidazole, a mixture of these oximes is dissolved in a water miscible organic solvent selected from methyl ethyl ketone, methanol, ethanol, isopropanol, acetonitrile, dimethylacetamide, dimethyl sulfoxide and, preferably, acetone, a sufficient quantity of water is added to initiate crystallization, and the precipitated anti oxime isomer which displays good antiviral activity is separated, e.g. in greater than about 95% purity.

    摘要翻译: 为了分离下式的顺式和反式肟... 其中R 1是C 1 -C 5烷基; 或R 2为苯基,或被C 1 -C 4烷基,C 1 -C 4烷氧基,氯,溴,碘,硝基或三氟甲基取代的苯基。 1-异丙基磺酰基-2-氨基-6-(α-羟基肟基苄基) - 苯并咪唑,将这些肟的混合物溶于选自甲基乙基酮,甲醇,乙醇,异丙醇,乙腈,二甲基乙酰胺,二甲基亚砜的水混溶性有机溶剂和 ,优选丙酮,加入足量的水以引发结晶,并且分离出显示良好抗病毒活性的沉淀的抗肟异构体,例如 大于约95%的纯度。